Sponsored Links
Results 1 to 2 of 2
  1. #1
    Adrian Di Bisceglie is offline Newbie 510 points
    Join Date
    Mar 2008
    Posts
    5
    Downloads
    0
    Uploads
    0
    Thanks
    0
    Thanked 0 Times in 0 Posts

    Treating liver diseases with viral etiology with activated Nigella sativa

    Advertisements



    The invention relates to compositions Activated Nigella sativa, which are useful in treating liver diseases, particularly those with viral etiology as HCV.
    (anybody have information about this thead)

  2. #2
    Adrian Di Bisceglie is offline Newbie 510 points
    Join Date
    Mar 2008
    Posts
    5
    Downloads
    0
    Uploads
    0
    Thanks
    0
    Thanked 0 Times in 0 Posts

    The Role of Naturally Activated N. Sativa capsules as an Effecti


    The Role of Naturally Activated Nigella Sativa Rab. capsules as an Effective Antiviral Drug in Hepatitis C Virus and its Complications
    JM.AIACHE et al.
    Laboratoire de Biopharmacie, Université d’Auvergne, Clermont-Ferrand, France, Department of Clinical Pharmaceutics,

    Purpose : The study is aiming to determine the efficacy and tolerance of the new invented naturally activated Nigella sativa (Rabicabir) which exist in Original Baraka capsules as a basic antiviral treatment of hepatitis C virus and its complications.

    Abstract : One hundred patients with chronic active hepatitis C virus cofirmed histopathologically and associated with high HCV-RNA PCR quantitatively were treated with the new invented drug extract which is registered as(Rabicabir) capsules; the activation know-how was developped in France through “Laboratoire d’Innovation in design and development drugs delivery devices “ which located in Clermont-ferrand.
    Medical statistical analysis of Random 100 patients of HCV were treated by the new invented drug in multi-hepatological centers all over Egypt in the period from January 2002 to October 2005.
    Laboratory investigations found that; by liver function tests, Rabicabir capsules(27)show normalized liver enzymes in all patients; by HCV-RNA PCR quantitative assessment, Rabicabir capsules who show significant improvement of HCV viraemia level (31).
    Radiological investigations found that ultrasonography abdomen examination(32,33) found that; for liver examination, Rabicabir capsules show significant improvement of liver condition, size and parenchymal affection in 67.5% of patients; for portal vein diameter, Rabicabir capsules show significant improvement and normalization of portal vein diameter and pressure in all patients; also for spleen examination, Rabicabir capsules show significant improvement of spleen condition, size and activity in 96% of patients.

    On the level of liver biopsy(34,35,36,39,46) and histopathological examination, it was found that for HCV chronic hepatitis activity scoring, Rabicabir capsules show 69% of patients improved and become mild HCV activity score while 1% of patients showed complete assisted activity while the rest 30% showed less improvement.

    On the level of general conditions (37,38)of the patients, Rabicabir capsules show improvement of general condition of 98% of patients where Rabicabir capsules improve the effort of the patient, no fatigue, no exhaustion, increase the appetite, sensation of nausea is disappeared, sensation of spasms in the right hand side of the abdomen is disappeared, dark pigmentation on the face and legs is disappeared, no weakness, patients gain weight again and the pale yellow colour on eye and nails were disappeared gradually which indicates that liver starts to work again also daily bleeding from different areas like nose, gum and mouth was significantly decreased with significant elevation of prothrombin secretion from the liver cells.

    On the level of liver fibrosis(40- 45) grading system, Rabicabir capsules showed 65% of patients improved and had mild liver fibrosis while 10% of patients got significant improvement and had very minimal fibrosis while the rest 25% of patients showed minimal improvement of liver fibrosis. The new invented drug is given to HCV patients with their approval consent in a dose of three grams per day after meals for a period ranged from 24-48 months according to HCV viraemia severity and liver condition. The new invented drug Rabicabir capsules is safe without any adverse reactions and has very good tolerability.

Similar Threads

  1. Activated Nigella sativa (Original Baraka) is a safe and potent antiviral th
    By rabicabir in forum Main European Medical Schools Forum
    Replies: 3
    Last Post: 11-21-2010, 08:28 AM
  2. The treatment information of Liver diseases
    By tokoyo7788 in forum Main European Medical Schools Forum
    Replies: 0
    Last Post: 04-05-2008, 02:10 AM

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •